← Back to Search

CDS + HHFNC Weaning for Bronchiolitis (REST EEC Trial)

N/A

Recruiting

Led By Christopher Horvat, MD

Research Sponsored by University of Pittsburgh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

<2 years of age Bronchiolitis WOB Score >2

Be younger than 18 years old

Must not have

Chronic lung disease

Congenital heart disease with baseline cardiorespiratory manifestations

Timeline

Screening 3 weeks

Treatment Varies

Follow Up days from admission to discharge from hospital or date of death, up to 90 days. of note, an earlier outcome was listed for 90-day cost of care and the redundancy with this outcome was recognized, so the 90-day cost of care outcome was removed.

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to improve recovery from common pediatric respiratory illnesses, reduce costs, and show UPMC Children's Hospital's capabilities in pediatric healthcare. It will examine using CDS to improve adherence to standardized guidelines and outcomes.

Who is the study for?

This trial is for children under 2 years old with bronchiolitis and a work of breathing (WOB) score greater than 2. It's not suitable for kids with congenital heart disease affecting their breathing, those who have weakened immune systems, or chronic lung conditions.

What is being tested?

The study tests if using Clinical Decision Support (CDS) can help doctors better follow guidelines when starting and adjusting heated high flow nasal cannula (HHFNC) therapy in young patients with bronchiolitis to improve recovery outcomes.

What are the potential side effects?

While the trial focuses on treatment management rather than medication side effects, HHFNC may cause nasal discomfort or irritation, dryness of the airways, or possible difficulty in weaning off due to dependency.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My child is under 2 years old with a severe breathing difficulty score over 2.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a long-term lung condition.

Select...

I was born with a heart condition that affects my breathing and heart function.

Select...

My immune system is weak.

Select...

My immune system is weakened.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ days from admission to discharge from hospital or date of death, up to 90 days. of note, an earlier outcome was listed for 90-day cost of care and the redundancy with this outcome was recognized, so the 90-day cost of care outcome was removed.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~days from admission to discharge from hospital or date of death, up to 90 days. of note, an earlier outcome was listed for 90-day cost of care and the redundancy with this outcome was recognized, so the 90-day cost of care outcome was removed.

This trial's timeline: 3 weeks for screening, Varies for treatment, and days from admission to discharge from hospital or date of death, up to 90 days. of note, an earlier outcome was listed for 90-day cost of care and the redundancy with this outcome was recognized, so the 90-day cost of care outcome was removed. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

HFNC duration

Secondary study objectives

Cost of hospitalization

Hospital length of stay

Mortality

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: HHFNC + Clinical decision SupportExperimental Treatment2 Interventions

Standardized HHFNC weaning coupled with clinical decision support consisting of electronic record embedded reminders to the clinical team to wean HHFNC

Group II: HHFNC WeaningActive Control2 Interventions

Team does not receive clinical decision support reminders to wean the HHFNC

0 / 5Eligibility criteria met